Malignant Pleural Effusion Market Expected to rise, 2034 | RS Oncology, Genelux Corporation, Candel Therapeutics, expected to boost the market

Posted on
by

Malignant Pleural Effusion Market Expected to rise, 2034 | RS Oncology, Genelux Corporation, Candel Therapeutics, expected to boost the market
Malignant Pleural Effusion Market Expected to rise by 2034, DelveInsight
The Malignant Pleural Effusion market growth is driven by factors like increase in the prevalence of Malignant Pleural Effusion, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Malignant Pleural Effusion market report also offers comprehensive insights into the Malignant Pleural Effusion market size, share, Malignant Pleural Effusion epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Malignant Pleural Effusion market size growth forward.

Some of the key highlights from the Malignant Pleural Effusion Market Insights Report:

  • In September 2024, the U.S. Food and Drug Administration (FDA) approved Merck’s anti-PD-1 therapy, KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). This approval marked the first indication for KEYTRUDA in MPM in the U.S.

  • The Malignant Pleural Effusion (MPE) market across the 7MM is projected to experience steady growth, with a moderate CAGR expected by 2034.

  • Malignant pleural effusion occurs when cancerous fluid accumulates between the lung and chest wall, causing symptoms such as breathing difficulties and chest discomfort. This condition is a common complication of various cancer types.

  • The United States accounts for the largest share—around 38%—of incident MPE cases within the 7MM. Among the EU4 and the UK, Germany has the highest proportion of diagnosed MPE cases at approximately 26%, while Spain has the lowest, making up about 15% of diagnosed cases.

  • An estimated 25% of total malignant pleural effusion cases go undiagnosed, likely due to their asymptomatic nature.

  • Among different tumor types, lung cancer is the leading cause of MPE cases. In 2023, approximately 30% of the total incident cases of MPE in the U.S. were linked to lung cancer.

  • In June 2024, RS Oncology, a privately held biopharmaceutical company focused on developing therapies for rare and aggressive cancers, presented positive Phase I study results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The study involved patients with Malignant Pleural Mesothelioma (MPM) with MPE or MPE associated with other solid tumors.

  • As of today, no approved drug exists for the treatment of malignant pleural effusion. Patients typically undergo chemotherapy, radiation therapy, or direct medication infusion into the chest cavity.

  • For recurrent MPE cases, a sclerosing agent may be introduced into the pleural cavity through tube thoracostomy to induce pleural fibrosis. This process, known as pleural sclerosis, utilizes agents like talc, doxycycline, and tetracycline and has an approximate 50% success rate in preventing effusion recurrence.

  • The pipeline for malignant pleural effusion treatments remains relatively small, presenting a potential opportunity for pharmaceutical companies. This limited pipeline may be attributed to the high mortality rate associated with the condition.

  • The scarcity of companies developing treatments for MPE could significantly shape future market dynamics. RS Oncology, currently advancing its drug through Phase I/II trials with promising results, may attract interest from larger pharmaceutical players, potentially driving innovation and new therapeutic approaches for this condition.

  • Several key pharmaceutical companies, including RS Oncology, Genelux Corporation, Candel Therapeutics, and others, are developing novel products to improve the Malignant Pleural Effusion treatment outlook.

  • Malignant Pleural Effusion therapies are RSO-021, and others.

  • As per DelveInsight analysis, the Malignant Pleural Effusion market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Malignant Pleural Effusion Market Landscape

Malignant Pleural Effusion Overview

Malignant pleural effusion is a condition in which fluid containing cancerous cells builds up in the space between the lung and the chest wall, causing symptoms such as difficulty breathing and chest discomfort. This complication is commonly associated with various types of cancer. The severity of symptoms varies, with some individuals remaining asymptomatic while others experience significant distress.

Do you know the treatment paradigms for different countries? Download our Malignant Pleural Effusion Market Sample Report

Malignant Pleural Effusion Epidemiology Insights

  • In the 7MM, the United States had the highest number of incident pleural effusion cases, comprising approximately 40% of the total cases in 2023.

  • Within the U.S., about 75% of all malignant pleural effusion cases were diagnosed, while the remaining cases went undiagnosed.

  • Among the EU4 and the UK, Germany recorded the highest number of diagnosed malignant pleural effusion cases, accounting for around 25% of the total diagnosed cases in the region.

  • By tumor type, malignant pleural effusion was most frequently associated with lung cancer in the 7MM, representing roughly 30% of diagnosed cases, followed by breast cancer.

Malignant Pleural Effusion Epidemiology Segmentation

DelveInsight’s Malignant Pleural Effusion market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Malignant Pleural Effusion historical patient pools and forecasted Malignant Pleural Effusion patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Malignant Pleural Effusion Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

  • Malignant Pleural Effusion Prevalence

  • Age-Specific Malignant Pleural Effusion Prevalence

  • Gender-Specific Malignant Pleural Effusion Prevalence

  • Diagnosed and Treatable Cases of Malignant Pleural Effusion

Visit for more @ Malignant Pleural Effusion Epidemiological Insights

Malignant Pleural Effusion Market Outlook

Only a few key players, such as RS Oncology, are advancing their lead candidates through Phase I/II clinical development, aiming to explore their potential for treating malignant pleural effusion.

Within the 7MM, the United States holds the largest market share in the malignant pleural effusion market.

Currently, there are no approved drugs for malignant pleural effusion, and the market is primarily driven by drainage procedures as the standard approach for managing the condition.

Malignant Pleural Effusion Emerging Therapies

  • RSO-021: RS Oncology

Malignant Pleural Effusion Key Companies

  • RS Oncology, Genelux Corporation, Candel Therapeutics, and others

For more information, visit Malignant Pleural Effusion Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Malignant Pleural Effusion Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Malignant Pleural Effusion, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Malignant Pleural Effusion epidemiology in the 7MM

  • Malignant Pleural Effusion marketed and emerging therapies

  • Malignant Pleural Effusion companies

  • Malignant Pleural Effusion market drivers and barriers

Table of Contents:

1 Malignant Pleural Effusion Market Key Comprehensive Insights

2 Malignant Pleural Effusion Market Report Introduction

3 Competitive Intelligence Analysis for Malignant Pleural Effusion

4 Malignant Pleural Effusion Market Analysis Overview at a Glance

5 Executive Summary of Malignant Pleural Effusion

6 Malignant Pleural Effusion Epidemiology and Market Methodology

7 Malignant Pleural Effusion Epidemiology and Patient Population

8 Malignant Pleural Effusion Patient Journey

9 Malignant Pleural Effusion Treatment Algorithm, Malignant Pleural Effusion Current Treatment, and Medical Practices

10 Key Endpoints in Malignant Pleural Effusion Clinical Trials

11 Malignant Pleural Effusion Marketed Therapies

12 Malignant Pleural Effusion Emerging Therapies

13 Malignant Pleural Effusion: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Malignant Pleural Effusion

16 Malignant Pleural Effusion Market Key Opinion Leaders Reviews

18 Malignant Pleural Effusion Market Drivers

19 Malignant Pleural Effusion Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Malignant Pleural Effusion Epidemiology 2034

DelveInsight’s “Malignant Pleural Effusion – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Malignant Pleural Effusion epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Malignant Pleural Effusion Pipeline 2024

“Malignant Pleural Effusion Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Malignant Pleural Effusion market. A detailed picture of the Malignant Pleural Effusion pipeline landscape is provided, which includes the disease overview and Malignant Pleural Effusion treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/